Citations

Showing 10 of 108152 citations.

Development of a Quantitative Antigen Assay to Detect Coccidioidal Chitinase-1 (CTS1)
Grill, Francisca J. , Grill, Marie , Roeder, Alexa J. , Blair, Janis E. , Lake, Douglas F. , Grys, Thomas E. , Grill, Marie F

Mayo Clinic

Open Forum Infectious Diseases | June 28, 2021 | Volume: 8 | Issue: 7 | Pages: No page available

10.1093/ofid/ofab344 | PMID 34337097 Get It

Abstract Background Coccidioidomycosis is often diagnosed with a collection of tests that measure a patient’s ability to mount an immune response to the fungus (antibody-based diagnostics) utilizing fungal protein preparations. Here we present an antigen-based assay that detects and quantifies coccidioidal chitinase-1 (CTS1) in diagnostic antigen preparations with potential for use in human serum. Methods An inhibition-based enzyme-linked immunoassay (ELISA) was developed that utilizes a monoclonal antibody specific for coccidioidal CTS1. CTS1 was quantified in commercial antigen preparations using recombinant CTS1 as a standard. Sera from 192 individuals from an endemic area were tested which included 78 patients (40.6%) with proven or probable coccidioidomycosis. Results The quantity of CTS1 in diagnostic commercial antigen preparations from different suppliers varied. Temporal constraints of availability of different lots of commercial antigens does not allow for immediate comparison of lot-to-lot variability. Assay results from patient serum samples correlated with low- and high-titer serology from patients with a coccidioidomycosis diagnosis. Further analysis suggested that patient derived anti-CTS1 antibodies may overlap with the mouse monoclonal antibody used in the assay. This unexpected overlap in CTS1 binding suggests the assay can detect antigen, antibody, or both, which contributes to its high level of clinical sensitivity of 89.74% and specificity of 94.90%. Conclusions The CTS1 inhibition ELISA described in this report is a promising tool to aid in quality control of antigens used in the diagnosis of coccidioidomycosis. Further optimization is needed to harness its utility as a diagnostic tool to aid in diagnosis and disease monitoring of coccidioidomycosis.
No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study
Dominguez–Valentin, Mev , Plazzer, John‐Paul , Sampson, Julian R. , Engel, Christoph , Aretz, Stefan , Sunde, Lone , Capellá, Gabriel , Balaguer, Francesc , Thomas, Huw , Evans, D. Gareth , Burn, John , Greenblatt, Marc S. , Cappel, Wouter H. de Vos tot Nederveen , Nielsen, Maartje , Bonanni, Bernardo , Tibiletti, Maria Grazia , Lindblom, Annika , Valle, Adriana Della , López-Köstner, Francisco, Gluck, Nathan , Katz, Lior H. , Heinimann, Karl , Vaccaro, Carlos , Nakken, Sigve , Hovig, Eivind , Green, Kate, Lalloo, Fiona, Hill, James , Perne, Claudia , Görgens, Heike, Holinski‐Feder, Elke , Holzapfel, Stefanie, Hüneburg, Robert , Doeberitz, Magnus von Knebel , Loeffler, Markus , Rahner, Nils, Steinke‐Lange, Verena , Schmiegel, Wolff , Vangala, Deepak , Crosbie, Emma J. , Pineda, Marta , Navarro, Matilde, Brunet, Joan , Moreira, Leticia , Sánchez, Ariadna , Serra‐Burriel, Miquel , Mints, Miriam, Kariv, Revital , Rosner, Guy , Piñero, Tamara Alejandra , Pavicic, Walter , Kalfayan, Pablo, Broeke, Sanne W. ten , Mecklin, Jukka‐Pekka , Pylvänäinen, Kirsi , Renkonen‐Sinisalo, Laura , Lepistö, Anna , Peltomäki, Païvi , Win, Aung Ko , Buchanan, Daniel D. , Lindor, Noralane M. , Gallinger, Steven , Marchand, Loı̈c Le , Figueiredo, Jane C. , Thibodeau, Stephen N. , Hansen, Thomas van Overeem , Lindberg, Lars Joachim , Rødland, Einar Andreas , Neffa, Florencia , Esperón, Patricia, Tjandra, Douglas , Seppälä, Toni T. , Møller, Pål , Capella, Gabriel , Balaguer, Francesc , Evans, D Gareth , Burn, John , de Vos Tot Nederveen Cappel, Wouter H , Nielsen, Maartje , Bonanni, Bernardo , Gluck, Nathan , Vaccaro, Carlos A , Nakken, Sigve , Hovig, Eivind , Hüneburg, Robert , Steinke-Lange, Verena , Vangala, Deepak , Crosbie, Emma J , Pineda, Marta , Brunet, Joan , Moreira, Leticia , Sánchez, Ariadna , Pavicic, Walter Hernán , Broeke, Sanne W Ten , Pylvänäinen, Kirsi , Win, Aung K , Buchanan, Daniel D , Marchand, Loïc Le , Rødland, Einar Andreas , Esperon, Patricia , Tjandra, Douglas , Seppälä, Toni T , Sunde, Lone , Engel, Christoph , Hansen, Thomas van Overeem , Lindblom, Annika , Jenkins, Mark A. , Bernstein, Inge , Macrae, Finlay , Winship, Ingrid , Sijmons, Rolf H. , Bertario, Lucio , Cavestro, Giulia Martina , Álvarez, Karin , Vasen, Hans F. A. , Büttner, Reinhard , Morak, Monika , Weitz, Jürgen , Mints, Miriam , Hopper, John L. , Newcomb, Polly A. , Therkildsen, Christina , Möslein, Gabriela

Mayo Clinic

Journal of Clinical Medicine | June 28, 2021 | Volume: 10 | Issue: 13 | Pages: 2856

10.3390/jcm10132856 | PMID 34203177 Get It

Background. Lynch syndrome is the most common genetic predisposition for hereditary cancer. Carriers of pathogenic changes in mismatch repair (MMR) genes have an increased risk of developing colorectal (CRC), endometrial, ovarian, urinary tract, prostate, and other cancers, depending on which gene is malfunctioning. In Lynch syndrome, differences in cancer incidence (penetrance) according to the gene involved have led to the stratification of cancer surveillance. By contrast, any differences in penetrance determined by the type of pathogenic variant remain unknown. Objective. To determine cumulative incidences of cancer in carriers of truncating and missense or aberrant splicing pathogenic variants of the MLH1 and MSH2 genes. Methods. Carriers of pathogenic variants of MLH1 (path_MLH1) and MSH2 (path_MSH2) genes filed in the Prospective Lynch Syndrome Database (PLSD) were categorized as truncating or missense/aberrant splicing according to the InSiGHT criteria for pathogenicity. Results. Among 5199 carriers, 1045 had missense or aberrant splicing variants, and 3930 had truncating variants. Prospective observation years for the two groups were 8205 and 34,141 years, respectively, after which there were no significant differences in incidences for cancer overall or for colorectal cancer or endometrial cancers separately. Conclusion. Truncating and missense or aberrant splicing pathogenic variants were associated with similar average cumulative incidences of cancer in carriers of path MLH1 and path_MSH2.
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes
Doran, Graeme, Cheung, Tak-Hong, Yim, So‐Fan, Yu, Mei‐Yung, Thorner, Aaron R. , Pedamallu, Chandra Sekhar , Lau, Kei-Man, Ducar, Matthew D. , Wong, Raymond R.Y., Wang, Vivian W., Nag, Anwesha , Wollison, Bruce M. , Dalgarno, Audrey, Lee, Jacqueline Ho Sze , Yeung, Suet-Ying, Wong, Lo , Leung, Shuk-On A., Mu, Yi , Mok, Samuel C. , Crum, Christopher P. , Chiu, Rossa W. K. , Berkowitz, Ross S. , Wong, Yick‐Fu, Thorner, Aaron R , Ducar, Matthew D , Lee, Jacqueline H S , Mok, Samuel C , Chung, Tony K.H. , Yim, So Fan, Worley, Michael J. , Elias, Kevin M. , Ojesina, Akinyemi I. , Yeung, Suet Ying, Horowitz, Neil S. , Davis, Michelle , Leung, Shuk On Annie , Chan, Paul K.S. , Lawrence, Michael S.

Mayo Clinic

Cancers | June 28, 2021 | Volume: 13 | Issue: 13 | Pages: 3218

10.3390/cancers13133218 | PMID 34203201 Get It

Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.
Diagnostic Accuracy of Dehydroepiandrosterone Sulfate and Corticotropin in Autonomous Cortisol Secretion
Carafone, Lindsay , Zhang, Catherine D , Li, Dingfeng , Lazik, Natalia, Hamidi, Oksana , Thomas, Melinda, Dy, Benzon M. , Lyden, Melanie L. , Foster, Trenton R. , McKenzie, Travis J. , Bancos, Irina , Hurtado, Maria Daniela , Thomas, Melinda A, Bancos, Irina , Hamidi, Oksana , Hurtado, Maria D. , Young, William F.

Mayo Clinic

Biomedicines | June 28, 2021 | Volume: 9 | Issue: 7 | Pages: 741

10.3390/biomedicines9070741 | PMID 34203283 Get It

Autonomous cortisol secretion (ACS) affects up to 50% of patients with adrenal adenomas. Despite the limited evidence, clinical guidelines recommend measurement of serum concentrations of dehydroepiandrosterone-sulfate (DHEA-S) and corticotropin (ACTH) to aid in the diagnosis of ACS. Our objective was to determine the accuracy of serum concentrations of DHEA-S and ACTH in diagnosing ACS. We conducted a retrospective single center study of adults with adrenal adenoma evaluated between 2000−2020. Main outcome measure was diagnostic accuracy of DHEA-S and ACTH. ACS was defined as post-dexamethasone cortisol >1.8 mcg/dL. Of 468 patients, ACS was diagnosed in 256 (55%) patients with a median post-DST cortisol of 3.45 mcg/dL (range, 1.9–32.7). Patients with ACS demonstrated lower serum concentrations of DHEA-S (35 vs. 87.3 mcg/dL, p < 0.0001) and ACTH (8.3 vs. 16 pg/mL, p < 0.0001) compared to patients with non-functioning adrenal tumors (NFAT). Serum DHEA-S concentration <40 mcg/dL diagnosed ACS with 84% specificity and 81% PPV, while serum ACTH concentration <10 pg/mL diagnosed ACS with 75% specificity and 78% PPV. The combination of serum concentrations of DHEA-S <40 mcg/dL and ACTH <10 pg/mL diagnosed ACS with the highest accuracy with 92% specificity and 87% PPV. Serum concentrations of DHEA-S and ACTH provide additional value in diagnosing ACS.
The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer
Gordetsky, Jennifer , Montgomery, Kathleen W., Giannico, Giovanna A. , Rais‐Bahrami, Soroush , Thapa, Prabin , Boorjian, Stephen A. , Frank, Igor, Craig, Jennifer , Cheville, John C. , Gordetsky, Jennifer B , Boorjian, Stephen

Mayo Clinic

International Journal of Surgical Pathology | June 28, 2021 | Volume: 30 | Issue: 1 | Pages: 6-14

10.1177/10668969211027264 | PMID 34180731 Get It

Objectives. To compare the clinicopathologic characteristics of urothelial carcinoma (UC), urothelial carcinoma with squamous differentiation (UCSD), and squamous cell carcinoma (SCC) of the bladder, which have been suggested to differ in terms of risk factors, immunophenotype, and prognosis. Methods. We evaluated the clinicopathologic features of radical cystectomy specimens between 1980 and 2015 with a diagnosis of SCC, UCSD, and UC. PD-L1 immunohistochemistry (clinically available clones 22C3, SP142, and SP263) was performed on SCC and UCSD. Multivariate Cox regression was used to identify prognostic factors. Kaplan–Meier curves were plotted to assess cancer-specific survival (CSS). Results. Of the 1478 cases, there were 1126 UC (76%), 217 UCSD (15%), and 135 SCC (9%). Bladder cancer was more common in men than women (80% vs 20%, P < .0001). However, a higher proportion of SCC and UCSD occurred in women (SCC-36%, UCSD-22%, UC-18%). Women were significantly more likely to be never smokers in all 3 cohorts (UC: 45% vs 16%, UCSD: 44% vs 12%, SCC: 40% vs 18%, P < .0001). Patients with SCC and UCSD were at a higher pathologic stage (>pT2) at the time of cystectomy (UCSD-74%, SCC 71%, UC-44%, P < .0001) and had worse CSS compared to patients with UC ( P = 0.006). SCC had higher PD-L1 scores (all clones) than UCSD ( P < .0001). PD-L1 22C3 ( P = .02, HR: 0.36) and SP142 scores ( P = .046, HR: 0.27) predicted CSS on Kaplan–Meier analysis for SCC cases. Conclusions. UC, UCSD, and SCC are associated with different risk factors, gender distributions, and clinical outcomes. PD-L1 is expressed in SCC and UCSD, suggesting some patients may benefit from targeted therapy.
Mesenchymal Stem/Stromal Cell–Derived Extracellular Vesicles for Chronic Kidney Disease: Are We There Yet?
Eirin, Alfonso , Lerman, Lilach O. , Eirin, Alfonso

Mayo Clinic

Hypertension | June 28, 2021 | Volume: 78 | Issue: 2 | Pages: 261-269

10.1161/hypertensionaha.121.14596 | PMID 34176287 Get It

Mesenchymal stem/stromal cells (MSCs) are the most utilized cell type for cellular therapy, partly due to their important proliferative potential and ability to differentiate into various cell types. MSCs produce large amounts of extracellular vesicles (EVs), which carry genetic and protein cargo to mediate MSC paracrine function. Recently, MSC-derived EVs have been successfully used in several preclinical models of chronic kidney disease. However, uncertainty remains regarding EV fate, safety, and long-term effects, which might impose important limitations on their path to clinical translation. This review discusses the therapeutic application of MSC-derived EV therapy for renal disease, with particular emphasis on potential mechanisms of kidney repair and major translational barriers. Emerging evidence indicates that the cargo of MSC-derived EVs is capable of modulating several pathways responsible for renal injury, including inflammation, oxidative stress, apoptosis, fibrosis, and microvascular remodeling. EV-induced modulation of these pathways has been associated with important renoprotective effects in experimental studies. However, scarce clinical data are available, and several challenges need to be addressed as we move toward clinical translation, including standardization of methods for EV isolation and characterization, EV fate, duration of EV effects, and effects of cardiovascular risk factors. MSC-derived EVs have the potential to preserve renal structure and function, but further experimental and clinical evidence is needed to confirm their protective effects in patients with chronic kidney disease.
Diagnosis of Pediatric Non-Esophageal Eosinophilic Gastrointestinal Disorders by Eosinophil Peroxidase Immunohistochemistry
Hasan, Shaina, Garg, Shipra , Doyle, Alfred D. , Bauer, Cindy S. , Wright, Benjamin L. , Schroeder, Shauna , Hasan, Shaina H, Garg, Shipra , Wright, Benjamin L , Taylor, Steve, Buras, Matthew

Mayo Clinic

Pediatric and Developmental Pathology | June 28, 2021 | Volume: 24 | Issue: 6 | Pages: 513-522

10.1177/10935266211024552 | PMID 34176359 Get It

Background Diagnosis of non-esophageal eosinophilic gastrointestinal disorders requires quantification of tissue eosinophils. Our objective was to evaluate eosinophil peroxidase (EPX) immunohistochemistry (IHC) as a method for histologic diagnosis of eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD). Methods We performed a retrospective analysis of biopsies from pediatric EG/EoD cases and controls. Subjects with EG or EoD had ≥30 eosinophils per high power field (eos/hpf) in ≥5 hpf in the stomach and/or ≥3 hpf in the duodenum, respectively. Controls had no histopathologic diagnosis recorded. Tissue eosinophil counts were assessed by hematoxylin & eosin stains. EPX stains were assessed using a unique histopathologic scoring system. Slides were digitized and EPX+ staining area/mm 2 was quantified by image analysis. Results Twenty-six EG/EoD cases and 40 controls were analyzed. EPX scores and EPX/mm 2 levels were markedly elevated in EG/EoD (p ≤ 0.0001). Eosinophil density (eos/mm 2 ) correlated strongly with EPX scores and EPX/mm 2 levels in the stomach (r ≥ 0.77) and moderately with EPX scores and EPX/mm 2 levels in the duodenum (r ≥ 0.52); (p < 0.0001). EPX quantification identified EG/EoD subjects with high diagnostic accuracy (EPX score: AUC = 1 for EG and EoD; EPX/mm 2 : AUC = 0.98 (95%CI 0.96-1) for EG, AUC = 0.91 (95%CI 0.81-1) for EoD). Conclusion EPX-based assessment of eosinophilic inflammation may facilitate automated histologic diagnosis.
Decline in Medicare Utilization and Reimbursement Rates in Ophthalmic Plastic and Reconstructive Surgery
Gong, Jung Ho, Khurana, Aditya, Eltorai, Adam E. M., Wagner, Lilly H., Wagner, Lilly H. , Gong, Jung Ho, Khurana, Aditya, Eltorai, Adam E. M., Wagner, Lilly H.

Mayo Clinic

Annals of Plastic Surgery | June 28, 2021 | Volume: 88 | Issue: 1 | Pages: 93-98

10.1097/sap.0000000000002925 | PMID 34176907 Get It

Background Analysis of current and past reimbursement patterns for federally funded programs is crucial to develop sustainable future payment models. Methods The Centers for Medicare and Medicaid Services Physician Fee Schedule was used to evaluate 26 common ophthalmic plastic and reconstructive surgery (OPRS) procedures. From 2010 to 2019, compound annual growth rate, total percent change, and annual percent change were calculated using inflation-adjusted reimbursement rates. Centers for Medicare and Medicaid Services’ Physician/Supplier Procedure Summary was used to assess the surgical volume of the 26 procedures in ophthalmology and plastic surgery services. Results From 2010 to 2019, total billed surgical procedures in OPRS decreased by 57.0%, affecting both ophthalmologists (−54.3%) and plastic surgeons (−80.1%). Over the study period, inflation-adjusted reimbursement rates decreased by 5.6%. Compound annual growth rate was −0.66%, and annual percent change was −0.62%. From 2010 to 2013, reimbursement rates increased by 1.8% each year. In contrast, from 2013 to 2019, reimbursement rates decreased by 1.7% each year (P < 0.0001). Conclusions From 2010 to 2019, Medicare utilization has substantially declined for OPRS procedures. Inflation-adjusted Medicare reimbursement rates have decreased for the majority of common procedures since 2013. Surgeons and policymakers need to be aware of these trends to ensure future availability of subspecialty surgical services.
BRASH: Case Report and Review of Literature
Sarkar, Sauradeep , Rapista, Nicole, Rout, Amit , Chaudhary, Rahul

Mayo Clinic

Hearts | June 27, 2021 | Volume: 2 | Issue: 3 | Pages: 302-306

10.3390/hearts2030025 Get It

BRASH syndrome is characterized by bradycardia, renal failure, AV nodal blockade, shock, and hyperkalemia. The proposed mechanism involves a vicious cycle between AV nodal blockers, hyperkalemia, and renal failure and was first described in 2016. We present a case of a 52-year-old woman who presented with progressively worsening shortness of breath and hypertensive urgency who subsequently developed profound bradycardia and shock that was refractory to resuscitative measures, she was diagnosed with BRASH syndrome. In this article, we explore the predisposing factors and challenges faced during the management of patients with BRASH syndrome.
European Heart Journal quality standards
Alfonso, Fernándo , Carter, Rickey E. , Carter, Rickey E , Torp-Pedersen, Christian Tobias , Crea, Filippo

Mayo Clinic

European Heart Journal | June 27, 2021 | Volume: 42 | Issue: 28 | Pages: 2729-2736

10.1093/eurheartj/ehab324 | PMID 34289494 Get It

Abstract The aim of the European Heart Journal (EHJ) is to attract innovative, methodologically sound, and clinically relevant research manuscripts able to change clinical practice and/or substantially advance knowledge on cardiovascular diseases. As the reference journal in cardiovascular medicine, the EHJ is committed to publishing only the best cardiovascular science adhering to the highest ethical principles. EHJ uses highly rigorous peer-review, critical statistical review and the highest quality editorial process, to ensure the novelty, accuracy, quality, and relevance of all accepted manuscripts with the aim of inspiring the clinical practice of EHJ readers and reducing the global burden of cardiovascular diseases. This review article summarizes the quality standards pursued by the EHJ to fulfill its mission.